Develops injectable biologic therapies that target disease-specific T cells for autoimmune and inflammatory diseases, and licensed cancer therapies for development by partners.
10-K for FY2025, filed Mar 16, 2026We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and…View ↗
CUE-100 series (Oncology): Selectively activate and expand tumor-specific T cells (e.g., CUE-101 for HPV+ cancers and CUE-102 for Wilms’…View ↗
Historically, we primarily focused our resources on the development of our CUE-100 series for oncology, namely the CUE-101 and CUE-102 drug…View ↗
Partners pay upfront fees for licenses, research and development support, and payments when development or sales milestones are reached; royalties may follow when licensed products are sold. License fees may be paid when the partner receives the rights, while research services can bring payments over the course of the work.
10-K for FY2025, filed Mar 16, 2026The Company recognizes collaboration revenue under certain of the Company’s license and collaboration agreements that are within the scope…View ↗
The Company recognizes collaboration revenue under certain of the Company’s license or collaboration agreements that are within the scope…View ↗
The terms of the Company’s arrangements with customers typically include the payment of one or more of the following: (i) non-refundable…View ↗
Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as…View ↗
$27.5M
10-K for FY2025, filed Mar 16, 2026
$27.5M ↗
Biopharmaceutical partners license drug candidates and may fund research and development activities. IMSCP received a license to develop CUE-101 and CUE-102 for oncology; Boehringer Ingelheim is developing CUE-501.
10-K for FY2025, filed Mar 16, 2026Historically, we primarily focused our resources on the development of our CUE-100 series for oncology, namely the CUE-101 and CUE-102 drug…View ↗
The CUE-500 series represents a novel approach to selectively target disease-causing cells by redirecting existing anti-viral memory T…View ↗
We intend to maximize this value by focusing on the development of CUE-401, for which we are preparing to file an IND application in the…View ↗
No. It lost $26.6M in FY2025.
10-Q for Q2 FY2026, filed Aug 14, 2026
−$153.1MView ↗
8-K, filed Sep 21, 2026
On September 20, 2026, the Company announced positive topline data from a Phase 2 clinical trial of CUE-221 in CSU conducted in China by…View ↗
8-K, filed May 1, 2026
On April 30, 2026, Cue Biopharma, Inc. (the “Company”) entered into a License Agreement (the “License Agreement”) with Ascendant Health…View ↗
8-K, filed Apr 7, 2026
On April 1, 2026, Cue Biopharma, Inc. (the “Company”) received notice from Boehringer Ingelheim that Boehringer Ingelheim had approved…View ↗
Growing. Revenue grew 84% in 4 years, from $14.9M in FY2021 to $27.5M in FY2025, about 16% a year.
Added an allergy drug candidate
The older report focused on developing its own T-cell-targeting biologics, especially cancer programs. The latest report includes an anti-IgE antibody licensed from Ascendant for allergic diseases, alongside its autoimmune programs.
10-K for FY2022, filed Mar 21, 2023 10-K for FY2025, filed Mar 16, 2026 8-K, filed May 1, 2026We are a clinical-stage biopharmaceutical company developing a novel class of injectable therapeutics engineered to selectively engage and…View ↗
BOSTON, Mass., April 30, 2026 — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of…View ↗
Shifted emphasis toward autoimmune programs
The older report prioritized cancer drug development and sought partners for programs outside oncology. The latest report emphasizes autoimmune drug development and describes collaborations for additional programs.
10-K for FY2022, filed Mar 21, 2023 10-K for FY2025, filed Mar 16, 2026We believe that we have demonstrated the potential of our engineered Immuno-STAT platform in treating cancer with the preliminary data from…View ↗
The pipeline chart below details our current portfolio of oncology assets and their stages of development. We have determined to prioritize…View ↗
Seek strategic partnerships and collaborations for our programs outside of oncologyView ↗
Competes with Amgen, Bristol-Myers Squibb, Merck &, Nektar Therapeutics, Sanofi, TRex Bio, RegCell, Coya Therapeutics, Quell Therapeutics, EVOQ Therapeutics, and Sonoma Biotherapeutics
10-K for FY2025, filed Mar 16, 2026We compete with other companies working to develop cytokines to restore immune balance, as well as those developing other therapeutic…View ↗
Loading...